Market Research Logo

EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2026

EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2026

Summary

Acute Myeloid Leukemia (AML), also known as myelogenous leukemia, acute myelocytic leukemia, or acute nonlymphocytic leukemia, is a rare cancer that accounts for a disproportionally high number of cancer-related deaths. The disease is more common in the elderly, and is relatively more common in men than in women (ACS, 2013; O’Donnell et al., 2012). AML starts in the bone marrow, where the developing white blood cells-including granulocytes and monocytes-mature abnormally, grow uncontrollably, and quickly overcrowd the blood, spreading into other parts of the body, including the lymph nodes, liver, and brain (ACS, 2013; ASCO, 2012). The symptoms are nonspecific and may include weight loss, fatigue, fever, problems with bleeding and clotting, and swelling of the liver and spleen (ACS, 2013).

In 2016, the 7MM had 43,592 diagnosed incident cases of AML. This is expected to increase to 52,526 diagnosed incident cases of AML by 2026, at an Annual Growth Rate (AGR) of 2.05%. The increase is driven by the aging population in the 7MM.

In 2016, the 7MM had 57,581 five-year diagnosed prevalent cases of AML. This is expected to increase to 66,743 by 2026, at an AGR of 1.54%. The US had the highest number of diagnosed incident and five-year prevalent cases of AML. The development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence.

Our epidemiologists provide a detailed segmentation of the diagnosed incident and five-year diagnosed prevalent cases of AML by subtypes and risk group classification, which are both important factors for predicting the prognosis in patients as well as specific treatment modalities for AML.

The report EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2026, provides an overview of the risk factors and the global and historical epidemiological trends for AML in the seven major markets (7MM): US, France, Germany, Italy, Spain, UK, and Japan.

In addition, this report also includes a 10-year epidemiological forecast for the following segmentations in adults ages 18 years and older across the 7MM -

  • Diagnosed incident cases of AML (adjusted for coding differences between cancer registries), segmented by ages 18-59 years and ages 60 years and older
  • Five-year diagnosed prevalent cases of AML, segmented by ages 18-59 years and ages 60 years and older
  • Diagnosed incident cases of APL and secondary AML, segmented by ages 18-59 years and ages 60 years and older
  • Diagnosed incident cases of AML with mutations (FLT3-ITD [internal tandem duplications], FLT3-TKD [tyrosine kinase domain], IDH [isocitrate dehydrogenase] 1 and IDH2), core binding factor (CBF) AML with KIT mutation, and biomarker CD33+
  • Diagnosed incident cases of AML classified into favorable-, intermediate-, and adverse-risk groups.
Scope
  • The Acute Myeloid Leukemia (AML) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of AML in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 7MM: diagnosed incident cases of AML, segmented by ages 18-59 years and ages 60 years and older; five-year diagnosed prevalent cases of AML, segmented by ages 18-59 years and ages 60 years and older; diagnosed incident cases of (acute promyelocytic leukemia) APL and secondary AML, segmented by ages 18-59 years and ages 60 years and older; diagnosed incident cases of AML with mutations (FLT3-ITD [internal tandem duplications], FLT3-TKD [tyrosine kinase domain], IDH [isocitrate dehydrogenase] 1 and IDH2), core binding factor (CBF) AML with KIT mutation, and biomarker CD33+; and diagnosed incident cases of AML classified into favorable-, intermediate-, and adverse-risk groups.
  • The AML epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The AML EpiCast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global AML market.
  • Quantify patient populations in the global AML market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AML therapeutics in each of the markets covered.
  • Identify the percentage of AML diagnosed incident and five-year diagnosed prevalent cases by various clinical segmentations.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Acute Myeloid Leukemia: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 Incidence
3.3.2 Relative Survival
3.3.3 Subtypes
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods - Population
3.4.3 Forecast Assumptions and Methods - Incidence
3.4.4 Forecast Assumptions and Methods - Relative Survival
3.4.5 Forecast Assumptions and Methods - Subtypes of AML
3.4.6 Forecast Assumptions and Methods - Mutations and Biomarkers
3.4.7 Forecast Assumptions and Methods - Risk Groups
3.5 Epidemiological Forecast for Acute Myeloid Leukemia (2016-2026)
3.5.1 Adjusted Diagnosed Incident Cases of AML
3.5.2 Age-Specific Diagnosed Incident Cases of AML
3.5.3 Diagnosed Incident Cases of APL
3.5.4 Diagnosed Incident Cases of Secondary AML
3.5.5 Diagnosed Incident Cases of AML by Mutations and Biomarkers
3.5.6 Diagnosed Incident Cases of AML by Risk Groups
3.5.7 Five-Year Diagnosed Prevalent Cases of AML
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer
1.1 List of Tables
Table 1: Risk Factors for AML in Adults
Table 2: AML Coding System by Country
Table 3: Five-Year Relative Survival of AML by Age, 2016
Table 4: Risk Group Classification Guidelines
Table 5: 7MM, Adjusted Diagnosed Incident Cases of AML, Ages ≥18 Years, Both Sexes, Select Years 2016-2026
Table 6: 7MM, Age-Specific Adjusted Diagnosed Incident Cases of AML, Both Sexes, 2016
Table 7: 7MM, Mutations and Biomarkers in Diagnosed Incident Cases of AML, Ages ≥18 Years, Both Sexes, 2016
Table 8: 7MM, Five-Year Diagnosed Prevalent Cases of AML, Ages ≥18 Years, Both Sexes, Select Years 2016-2026
1.2 List of Figures
Figure 1: 7MM, Adjusted Diagnosed Incident Cases of AML, Both Sexes, Ages ≥18 Years, 2016 and 2026
Figure 2: 7MM, Five-Year Diagnosed Prevalent Cases of AML, Both Sexes, Ages ≥18 Years, 2016 and 2026
Figure 3: 7MM, Age-Standardized Adjusted Diagnosed Incidence of AML, Ages ≥18 Years, 2016
Figure 4: 7MM, Sources Used and Not Used, Diagnosed Incident Cases of AML
Figure 5: 7MM Sources Used, Relative Survival of AML
Figure 6: 7MM, Sources Used, Diagnosed Incident Cases of APL
Figure 7: 7MM, Sources Used, Diagnosed Incident Cases of Secondary AML
Figure 8: 7MM, Diagnosed Incident Cases of APL, Both Sexes, Ages ≥18 Years, 2016
Figure 9: 7MM, Diagnosed Incident Cases of Secondary AML, Both Sexes, Ages ≥18 Years, 2016
Figure 10: 7MM, Diagnosed Incident Cases of AML by Risk Group, Both Sexes, Ages ≥18 Years, 2016
Figure 11: 7MM, Five-Year Diagnosed Prevalent Cases of AML by Age, Both Sexes, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report